Endometrial Cancer Trial, Recruiting NCT05876130 Sponsor: Samsung Medical Center Condition: Endometrial Cancer
Back to Endometrial Cancer

Endometrial Cancer Trial, Recruiting

NCT05876130
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been diagnosed with a specific type of uterine (womb) cancer called endometrioid endometrial cancer, confirmed through laboratory testing of tissue samples
  • People who have completed a hysterectomy (surgery to remove the uterus) along with surgical staging (surgery to determine how far the cancer has spread)
  • People whose cancer has been confirmed as Stage III (meaning the cancer has spread beyond the uterus but not to distant parts of the body) according to an international staging system called FIGO
  • People who are generally well enough to carry out light daily activities, with little to no restriction from their illness (confirmed with trial site)
  • People who have already received, or are planning to receive, chemotherapy after their surgery

Who may not be able to join:

  • People whose cancer has spread to distant parts of the body (such as other organs far from the original cancer site)
  • People who have previously had radiation therapy to the pelvic area
  • People who have a serious or unstable health condition (confirm with trial site)
  • People who have a history of another type of cancer, with the exception of thyroid cancer, skin cancer, or endometrial cancer

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 13 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Won Park, Samsung Medical Center

Phone: +82-2-3410-2612

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
1 November 2022
Est. completion
31 December 2031

Where this trial is recruiting

🇰🇷 South Korea

Primary endpoints

5-year disease-free survival rate

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 13 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov